3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Breast
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Sarcoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
19
Radiosurgery
16
Radiotherapy
14
Specimen Handling
11
Pemetrexed
8
Paclitaxel
6
Erlotinib Hydrochloride
6
Docetaxel
6
Carboplatin
6
Bevacizumab
5
pembrolizumab
4
Temozolomide
4
Spinal Puncture
4
Cisplatin
4
osimertinib
3
Taxes
3
Nivolumab
3
Gemcitabine
3
Gefitinib
3
Filgrastim
3
Drug Therapy
3
trametinib
2
selpercatinib
2
sapanisertib
2
motexafin gadolinium
2
epothilone B
2
dabrafenib
2
X-Rays
2
Vorinostat
2
Trastuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Interleukin-15
×
CNS
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled